Reply - 04/05/19
Doi : 10.1016/j.jaci.2019.01.041
Alberta L. Wang, MD, MS a, b 
, Kelan G. Tantisira, MD, MPH a, c
, Kelan G. Tantisira, MD, MPH a, c a Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass
b Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass
c Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass
Le texte complet de cet article est disponible en PDF.
| This study was supported by the National Institutes of Health (grant nos. T32 AI007306, R01 HL127332, R01 HL129935, and U01 HL65899). |
|
| Disclosure of potential conflict of interest: The authors declare that they have no relevant conflicts of interest. |
© 2019
American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 143 - N° 5
P. 1975 - mai 2019 Retour au numéro
Article précédent
- Applying the CAMP trial asthma remission prediction model to the Dutch asthma remission studies
- Orestes A. Carpaij, Judith M. Vonk, Martijn C. Nawijn, Huib A.M. Kerstjens, Gerard H. Koppelman, Maarten van den Berge
- Amoxicillin sensitization rate in patients with eruptions after Helicobacter pylori eradication therapy
- Kazuhiro Kawai
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?